Benzamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-4-nitro- manufacturers
|
| | Benzamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-4-nitro- Basic information |
| | Benzamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-4-nitro- Chemical Properties |
| Melting point | >320 °C(Solv: ethanol (64-17-5)) | | Boiling point | 470.4±45.0 °C(Predicted) | | density | 1.436±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF : 1.85 mg/mL (5.70 mM; ultrasonic and warming and heat to 60°C) | | pka | 11.05±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | Benzamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-4-nitro- Usage And Synthesis |
| Uses | Anti-inflammatory agent 34 (Compound IVf) is an orally active anti-inflammatory and analgesic agent[1]. | | in vivo | Anti-inflammatory agent 34 (Compound IVf) (200mg/kg; p.o.; single dose) shows inhibitory activity on carrageenan induced rat paw edema, and shows analgesic activity in mice[1]. | Animal Model: | Male albino rats, carrageenan-induced rat paw edema assay model[1] | | Dosage: | 200 mg/kg | | Administration: | Oral, single dose | | Result: | Showed 55.7 ± 0.019% inhibition on carrageenan induced rat paw edema at the 3rd h. |
| Animal Model: | Albino mice, acetic acid induced writhing method[1] | | Dosage: | 200 mg/kg | | Administration: | Oral, single dose | | Result: | Showed 48.1% analgesic activity. |
| | References | [1] Ronad PM, et al. Synthesis and evaluation of anti-inflammatory and analgesic activities of a novel series of substituted-N-(4-methyl-2-oxo-2H-chromen-7-yl) benzamides. Arzneimittelforschung. 2008;58(12):641-6. DOI:10.1055/s-0031-1296565 |
| | Benzamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-4-nitro- Preparation Products And Raw materials |
|